The family Hepadnaviridae comprises a distinctive group of small hepatotropic DNA viruses that primarily infect the liver cells of humans, mammals, and birds. The name “hepadnavirus” is derived from the words hepatic and DNA, reflecting the liver-associated nature of these viruses and their DNA-containing genomes. Members of this viral family are medically and economically important because they are associated with acute and chronic liver diseases, including hepatitis, liver cirrhosis, and hepatocellular carcinoma. Among all known hepadnaviruses, the human hepatitis B virus (HBV) is the most significant representative due to its widespread global distribution and its major contribution to chronic liver disease worldwide.
The Hepadnaviridae family is divided into two major genera: Orthohepadnavirus and Avihepadnavirus. The genus Orthohepadnavirus includes viruses that infect humans and other mammals such as primates, woodchucks, squirrels, and bats. Human hepatitis B virus belongs to this genus and serves as the prototype species of the family. The genus Avihepadnavirus contains viruses that infect birds, including ducks, cranes, herons, and storks. Duck hepatitis B virus (DHBV) is one of the best-known avian members and has been widely used as an experimental model for studying viral replication and pathogenesis.
Hepadnaviruses are unique among DNA viruses because they replicate through an RNA intermediate using reverse transcription. This replication strategy resembles that of retroviruses, although hepadnaviruses are genetically distinct from them. Their ability to establish chronic infections in the liver makes them important pathogens in both human and veterinary medicine. In humans, hepatitis B virus infection remains a major global health challenge, affecting millions of individuals and contributing significantly to liver-related morbidity and mortality.
Biology of hepadnaviruses
The biology of hepadnaviruses is characterized by their strong affinity for hepatocytes. Hepatocytes are the major functional cells of the liver. Viral infection begins when the virus attaches to specific receptors on the surface of liver cells through proteins located on the viral envelope. After attachment, the virus enters the host cell, and the nucleocapsid is transported into the nucleus where viral replication is initiated.
One of the most remarkable biological properties of the Hepadnaviridae family is its replication mechanism. Although the viral genome is composed of DNA, replication occurs through an RNA intermediate. Following entry into the nucleus, the partially double-stranded viral DNA is repaired and converted into covalently closed circular DNA (cccDNA), which serves as a stable transcriptional template. Host cellular enzymes transcribe this DNA into various viral RNAs, including the pregenomic RNA that is essential for viral replication.
Inside newly forming nucleocapsids, the viral polymerase enzyme carries out reverse transcription, converting the pregenomic RNA back into partially double-stranded DNA. This reverse transcription process is a defining feature of hepadnaviral biology and distinguishes these viruses from most other DNA viruses. Newly synthesized viral particles acquire their envelope from intracellular membranes before being released from the infected hepatocyte.
Hepadnaviruses are capable of causing both acute and chronic infections. Acute infection may result in inflammation of the liver, while chronic infection can persist for years and progressively damage hepatic tissues. Chronic hepatitis B infection is strongly associated with liver fibrosis, cirrhosis, and hepatocellular carcinoma. Viral persistence is largely due to the stability of cccDNA within the nucleus, which allows the virus to remain in infected cells for prolonged periods despite immune responses or antiviral therapy.
The viruses are generally sensitive to environmental factors such as heat, acids, detergents, ether, and organic solvents because of the lipid components present in their outer envelope. Disruption of the envelope interferes with viral infectivity by damaging the surface proteins required for host cell attachment. Despite this sensitivity, hepatitis B virus can remain infectious outside the body for several days under favorable environmental conditions, thereby enhancing its transmission through blood and body fluids.
Animal hepadnaviruses have also contributed significantly to scientific research. Experimental models involving duck hepatitis B virus and woodchuck hepatitis virus have improved understanding of viral persistence, immune responses, carcinogenesis, and antiviral drug development. These models continue to play an important role in advancing therapeutic strategies against hepatitis B virus infection.
Structure of hepadnaviruses
Hepadnaviruses are small, spherical, enveloped viruses with diameters ranging between approximately 40 and 48 nm. The complete infectious particle of hepatitis B virus is commonly referred to as the Dane particle. Structurally, the virion consists of an outer lipid envelope surrounding an inner nucleocapsid core that encloses the viral genome and associated enzymes (Figure 1).
The outer envelope contains viral glycoproteins known as hepatitis B surface antigens (HBsAg). These surface proteins are essential for viral attachment, entry into host cells, and immune recognition. The envelope itself is derived from host cell membranes during viral assembly and budding. In infected individuals, large quantities of noninfectious surface antigen particles may also circulate in the bloodstream, serving as important diagnostic markers of infection.
Beneath the envelope lies the nucleocapsid, an icosahedral structure primarily composed of hepatitis B core antigen (HBcAg). The nucleocapsid protects the viral genome and houses the viral polymerase enzyme responsible for DNA synthesis and reverse transcription. This enzyme possesses several functions, including DNA polymerase activity, reverse transcriptase activity, and ribonuclease activity.
The genome of hepadnaviruses is highly unusual and represents one of the defining structural features of the family. Hepatitis B virus is the only causative agent of viral hepatitis that contains a partially double-stranded circular DNA genome. The genome is relatively small, measuring approximately 3.2 kilobases in length, but it is highly compact and efficiently organized with overlapping open reading frames.
Four major genes are present within the viral genome: S, C, P, and X. The S gene encodes the surface antigens that form the viral envelope, while the C gene encodes the core proteins and hepatitis B e antigen (HBeAg). The P gene encodes the viral polymerase enzyme involved in replication and reverse transcription, whereas the X gene encodes a regulatory protein that plays a role in transcriptional activation and viral pathogenesis.
The compact organization of the genome allows the virus to maximize its coding capacity despite its small size. This structural efficiency contributes to the successful replication and persistence of hepadnaviruses within host cells. The unique structural organization of the Hepadnaviridae family, particularly its partially double-stranded DNA genome and reverse transcription mechanism, distinguishes these viruses from all other known hepatitis viruses.
Major viral agents of human hepatitis and the nosocomial significance of hepatitis B virus
Hepatitis refers to inflammation of the liver and is most commonly caused by viral infections. Viral hepatitis remains a major global public health concern because it contributes significantly to liver-related morbidity and mortality worldwide. The major causative agents of viral hepatitis in humans are:
- Hepatitis A virus (HAV),
- Hepatitis B virus (HBV),
- Hepatitis C virus (HCV),
- Hepatitis D virus (HDV), and
- Hepatitis E virus (HEV).
These viruses differ in their genomic composition, modes of transmission, pathogenicity, epidemiology, and clinical outcomes. Although all of them primarily affect the liver, their biological characteristics and mechanisms of spread vary considerably.
Hepatitis A virus belongs to the family Picornaviridae and possesses a single-stranded RNA (ssRNA) genome. HAV is mainly transmitted through the fecal-oral route, usually via ingestion of contaminated food or water. Poor sanitation, overcrowding, and inadequate hygiene practices are important factors that facilitate transmission. Hepatitis A infection is generally acute and self-limiting, and it rarely progresses to chronic liver disease. Symptoms commonly include fever, fatigue, nausea, abdominal discomfort, and jaundice. Vaccination and proper sanitation remain the most effective preventive measures against HAV infection.
Hepatitis B virus belongs to the family Hepadnaviridae and is unique among hepatitis viruses because it possesses a partially double-stranded DNA (dsDNA) genome. HBV is transmitted primarily through sexual contact, exposure to infected blood and body fluids, and vertical transmission from infected mothers to their infants during childbirth. Unlike hepatitis A, HBV can cause both acute and chronic infections. Chronic HBV infection may persist for years and can lead to severe complications such as liver cirrhosis, liver failure, and hepatocellular carcinoma. HBV is also biologically unique because it replicates through reverse transcription using a viral reverse transcriptase enzyme, a feature similar to retroviruses such as HIV.
Hepatitis C virus is a member of the family Flaviviridae and contains a single-stranded RNA genome. Similar to HBV, HCV is primarily transmitted through contaminated blood, sexual contact, and mother-to-child transmission. Intravenous drug use and transfusion of unscreened blood products are major risk factors for HCV infection. Acute infection may be asymptomatic, but a large proportion of infected individuals develop chronic hepatitis, which may progress to cirrhosis and hepatocellular carcinoma. Unlike HBV, there is currently no vaccine available for HCV, although highly effective antiviral therapies have greatly improved treatment outcomes.
Hepatitis D virus, also known as delta virus, possesses a single-stranded RNA genome and is classified within the genus Deltavirus. HDV is considered a defective virus because it requires the presence of hepatitis B virus for replication and infectivity. HDV infection occurs either as a co-infection with HBV or as a superinfection in individuals already chronically infected with HBV. Transmission occurs mainly through parenteral exposure to infected blood and body fluids. HDV infection often worsens liver disease severity and accelerates progression to cirrhosis and liver failure.
Hepatitis E virus belongs to the family Hepeviridae and possesses a single-stranded RNA genome. Similar to hepatitis A virus, HEV is mainly transmitted through the fecal-oral route, particularly through contaminated drinking water. Outbreaks are more common in areas with poor sanitation and inadequate water treatment facilities. In most individuals, hepatitis E infection is self-limiting; however, severe disease may occur in pregnant women and immunocompromised individuals, where mortality rates can be significantly higher.
Among all hepatitis viruses, hepatitis B virus remains one of the most clinically significant due to its high infectivity, chronic disease potential, and ability to spread efficiently in healthcare environments. HBV infection is recognized as an important nosocomial infection because it can easily spread within hospitals, clinics, laboratories, and other healthcare settings through contact with infected blood and contaminated body fluids. Nosocomial transmission refers to infections acquired within healthcare facilities and is often associated with inadequate infection-control practices.
Healthcare workers, laboratory personnel, surgeons, nurses, dentists, and other hospital staff are particularly at risk of occupational exposure to HBV because of frequent contact with blood, needles, and contaminated medical instruments. The virus can be transmitted through accidental needle-stick injuries, cuts from contaminated sharp instruments, exposure of broken skin to infected blood, or contact of infectious fluids with mucous membranes. Medical equipment such as syringes, scalpels, scissors, surgical instruments, dialysis equipment, and improperly sterilized devices may serve as vehicles for transmission if strict sterilization procedures are not followed.
HBV is highly infectious and can survive outside the human body for several days under favorable environmental conditions. This environmental stability contributes significantly to its ability to spread within healthcare settings. Blood-contaminated surfaces, improperly disposed sharps, and reused medical equipment can all facilitate nosocomial outbreaks. Consequently, strict adherence to infection-prevention and control measures is essential in reducing occupational and hospital-acquired HBV infections.
The use of personal protective equipment (PPE) is one of the most effective preventive strategies against nosocomial transmission of HBV. Healthcare workers and laboratory personnel are required to wear protective coverings such as gloves, laboratory coats, gowns, face masks, and eye protection when handling patients, blood samples, or potentially infectious materials. Gloves provide an important barrier against direct contact with infected blood and body fluids, while gowns and laboratory coats protect skin and clothing from contamination.
Proper handling and disposal of sharps such as needles, lancets, and scalpels are also critical components of infection control. Used needles should never be recapped by hand and must be discarded immediately into puncture-resistant sharps containers. Reuse of disposable syringes and needles should be strictly prohibited. In addition, all reusable medical equipment must undergo proper sterilization and disinfection before subsequent use.
Laboratory safety practices are equally important in preventing HBV transmission. All blood samples and clinical specimens should be treated as potentially infectious regardless of the patient’s diagnosis. This principle, known as universal precaution, requires healthcare workers to consistently apply infection-control measures to all specimens and patients. Blood spills should be cleaned immediately using appropriate disinfectants, and contaminated materials should be disposed of safely according to biomedical waste management guidelines.
Vaccination against hepatitis B remains one of the most effective preventive measures for healthcare-associated HBV infection. Hepatitis B vaccine induces protective immunity and significantly reduces the risk of occupational exposure among healthcare personnel. Vaccination is strongly recommended for healthcare workers, laboratory staff, medical students, and other individuals at increased risk of exposure to blood and body fluids. Post-vaccination testing may also be performed to confirm adequate immune protection.
Public health education and continuous training of healthcare personnel are essential for improving compliance with infection-control procedures. Hospitals and laboratories should establish comprehensive biosafety guidelines and ensure that staff members are adequately trained in safe specimen handling, waste disposal, sterilization techniques, and emergency management of accidental exposures.
Hepatitis B Virus: A Unique DNA Virus with Retrovirus-Like Replication
HBV is one of the most medically important members of the family Hepadnaviridae and remains a major global cause of liver disease. Unlike the other major causative agents of viral hepatitis in humans, such as hepatitis A virus (HAV), hepatitis C virus (HCV), and hepatitis E virus (HEV), whose genomes are composed of single-stranded RNA (ssRNA), HBV possesses a partially double-stranded DNA genome. This characteristic makes HBV unique among hepatitis viruses and contributes significantly to its distinctive replication strategy and pathogenicity.
HBV is also exceptional because, despite being a DNA virus, it replicates through an RNA intermediate using a virally encoded reverse transcriptase (RT) enzyme. This feature is similar to the replication strategy employed by retroviruses such as human immunodeficiency virus (HIV). During replication, HBV synthesizes viral DNA from a pregenomic RNA template through reverse transcription, creating an RNA-DNA replication pathway. This unusual mechanism distinguishes HBV from most conventional DNA viruses and contributes to its ability to establish persistent infections.
The virus exhibits a strong tropism for hepatocytes, the major functional cells of the liver. Viral replication primarily occurs within these cells, leading to varying degrees of liver inflammation and tissue damage. HBV contains several important structural proteins, particularly hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg), both of which play critical roles in viral infectivity, immune evasion, diagnosis, and disease progression. While HBcAg is mainly localized within infected hepatocytes, HBsAg is abundantly expressed on the surface of viral particles and released into the bloodstream during active viral replication.
HBV infection is a major public health concern because it can cause both acute and chronic hepatitis. Chronic infection significantly increases the risk of severe liver complications, including cirrhosis and hepatocellular carcinoma. Despite the availability of effective vaccines and antiviral therapies, HBV continues to affect millions of people worldwide, particularly in regions with limited healthcare resources.
Pathogenesis of hepatitis B virus
The pathogenesis of HBV infection begins when the virus enters the body through exposure to infected blood or body fluids. The major routes of transmission include sexual contact, parenteral exposure to contaminated blood, sharing of needles or sharp objects, and vertical transmission from an infected mother to her unborn child during childbirth. Transmission through unsafe injections, tattooing, acupuncture, and transfusion of contaminated blood products also contributes significantly to the spread of infection.
Certain populations are at particularly high risk of acquiring HBV infection. These include intravenous drug users, healthcare workers exposed to blood and body fluids, individuals with multiple sexual partners, sex workers, men who have sex with men, recipients of unscreened blood transfusions, and individuals who share razors, needles, or other sharp instruments. In endemic regions, mother-to-child transmission remains one of the most important mechanisms responsible for chronic infection in children.
After entering the bloodstream, HBV reaches the liver and specifically infects hepatocytes. The virus attaches to receptors on the surface of liver cells and enters through receptor-mediated endocytosis. Once inside the hepatocyte, the viral nucleocapsid migrates to the nucleus, where the partially double-stranded DNA genome is repaired and converted into covalently closed circular DNA (cccDNA). This cccDNA acts as a stable template for viral replication and is responsible for the persistence of infection within liver cells.
The incubation period of HBV infection ranges from approximately six weeks to six months, depending on the viral dose, host immune status, and route of exposure. During this period, viral replication occurs actively within hepatocytes, although symptoms may not yet be evident. The pathogenesis of liver injury in HBV infection is primarily immune-mediated rather than due to direct cytopathic effects of the virus itself. Cytotoxic T lymphocytes recognize infected hepatocytes and initiate immune responses aimed at eliminating infected cells. While this immune response helps control infection, it also contributes to liver inflammation and tissue damage.
Acute HBV infection may present with fever, fatigue, nausea, abdominal pain, anorexia, dark urine, and jaundice resulting from impaired bilirubin metabolism. In many individuals, especially adults with competent immune systems, the infection is self-limiting and eventually resolves with complete viral clearance. These individuals develop protective immunity characterized by the production of antibodies against HBsAg.
However, in some individuals, particularly neonates and immunocompromised patients, the virus is not effectively cleared, resulting in chronic infection. Chronic hepatitis B is characterized by persistent viral replication and continuous liver inflammation. Long-term infection may progressively lead to fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Chronic HBV infection is one of the leading causes of liver cancer worldwide because persistent inflammation and repeated cycles of hepatocyte injury and regeneration promote malignant transformation.
The ability of HBV to persist within hepatocytes is largely attributed to the stability of cccDNA and the virus’s capacity to evade immune responses. Continuous expression of viral antigens, especially HBsAg, may also contribute to immune exhaustion and impaired antiviral immunity, allowing the virus to remain within the host for prolonged periods.
Detection and diagnosis of HBV
The diagnosis of HBV infection involves the detection of viral antigens, antibodies, viral DNA, and liver function abnormalities. Laboratory diagnosis is essential for identifying acute infection, chronic infection, carrier states, and immunity following vaccination or recovery. One of the most important diagnostic markers is hepatitis B surface antigen (HBsAg). The presence of HBsAg in blood indicates active HBV infection and is usually the first detectable viral marker during acute infection. Persistence of HBsAg for more than six months is generally indicative of chronic hepatitis B infection.
Hepatitis B core antigen (HBcAg) is primarily found within infected hepatocytes and is not commonly detected freely in serum. However, antibodies against HBcAg, particularly anti-HBc IgM and IgG antibodies, are important serological markers. Anti-HBc IgM indicates recent or acute infection, while anti-HBc IgG suggests previous exposure or chronic infection. Another important marker is hepatitis B e antigen (HBeAg), which is associated with active viral replication and high infectivity. The presence of HBeAg usually indicates increased transmission potential, whereas antibodies against HBeAg suggest reduced viral replication.
Molecular diagnostic techniques such as polymerase chain reaction (PCR) are widely used for the detection and quantification of HBV DNA in blood samples. Measurement of viral load is particularly important in monitoring disease progression, evaluating infectivity, and assessing response to antiviral therapy. PCR-based assays are highly sensitive and can detect low levels of viral DNA even before serological markers become apparent. Liver function tests are also important in the evaluation of HBV infection. Elevated levels of liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) indicate hepatocellular injury and inflammation. Imaging studies and liver biopsy may be performed in chronic cases to assess the degree of fibrosis, cirrhosis, or liver cancer development.
Rapid diagnostic tests and enzyme-linked immunosorbent assays (ELISA) are commonly employed for routine screening of blood donors, pregnant women, healthcare workers, and high-risk populations. Early detection is essential for preventing transmission and initiating appropriate management.
Treatment and prevention of HBV infection
The management of HBV infection depends on whether the disease is acute or chronic. Acute hepatitis B infection is often self-limiting, and many immunocompetent adults recover spontaneously without specific antiviral therapy. Treatment in acute cases is generally supportive and focuses on maintaining hydration, nutrition, and liver function while avoiding hepatotoxic substances such as alcohol and certain medications.
Chronic hepatitis B infection requires long-term monitoring and, in many cases, antiviral treatment. The primary goals of therapy are to suppress viral replication, reduce liver inflammation, prevent progression to cirrhosis and hepatocellular carcinoma, and improve long-term survival.
Several antiviral drugs are currently used in the treatment of chronic HBV infection. Nucleoside and nucleotide analogs such as tenofovir and entecavir inhibit the activity of viral reverse transcriptase and effectively suppress HBV DNA replication. These agents are preferred because they are highly potent and associated with lower rates of drug resistance. Other antiviral agents previously used include lamivudine, adefovir, and telbivudine, although resistance may develop during prolonged therapy.
Interferon-alpha therapy may also be used in selected patients. Interferons enhance host immune responses against HBV and can lead to sustained viral suppression in some individuals. However, interferon therapy is associated with significant side effects and is not suitable for all patients. Despite the effectiveness of antiviral therapy, complete eradication of HBV is difficult because cccDNA persists within hepatocyte nuclei. Consequently, many patients require prolonged or lifelong treatment and regular monitoring for liver complications.
Epidemiology of hepadnaviral infections
Viruses belonging to the family Hepadnaviridae are important causes of liver disease in humans and animals. The most significant member of this family is HBV, which belongs to the genus Orthohepadnavirus. HBV is one of the most widespread viral pathogens globally and remains a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. The infection affects millions of individuals worldwide and contributes substantially to liver-related morbidity and mortality, particularly in developing countries where healthcare resources may be limited.
The epidemiology of HBV infection differs across geographical regions. High endemicity areas include sub-Saharan Africa, Southeast Asia, and parts of the Western Pacific, where transmission commonly occurs during infancy or early childhood. In these regions, chronic infection rates are high because infections acquired early in life are more likely to persist. In contrast, low endemicity regions such as North America and Western Europe mainly report infections among adults through high-risk behaviors and occupational exposure.
HBV is transmitted primarily through contact with infected blood and body fluids. The major routes of transmission include sexual contact, exposure to contaminated blood, sharing of infected needles or sharp objects, and vertical transmission from infected mothers to newborns during childbirth. Unsafe injections, blood transfusion with unscreened blood products, tattooing, acupuncture, and poor infection-control practices also contribute to disease spread.
Certain populations are at greater risk of HBV infection, including healthcare workers, laboratory personnel, intravenous drug users, sex workers, individuals with multiple sexual partners, and recipients of unscreened blood transfusions. Nosocomial transmission within healthcare settings remains an important concern because HBV is highly infectious and can survive outside the body for several days under favorable conditions. Chronic HBV carriers serve as important reservoirs for continued viral transmission within communities. The persistence of chronic infection and the long-term complications associated with HBV make it one of the most important viral infections affecting global public health.
Prevention and control of hepadnaviral infections
Prevention and control of infections caused by members of the Hepadnaviridae family rely mainly on vaccination, proper infection-control practices, public health education, and early diagnosis. Vaccination against hepatitis B virus remains the most effective preventive measure and has significantly reduced the prevalence of HBV infection in countries with successful immunization programs. The hepatitis B vaccine contains recombinant HBsAg, which stimulates protective immunity against the virus.
Universal childhood immunization is strongly recommended because early vaccination prevents both acute infection and chronic carrier states. Infants born to HBV-infected mothers should receive hepatitis B vaccine and hepatitis B immunoglobulin immediately after birth to reduce vertical transmission. Vaccination is also recommended for healthcare workers, laboratory personnel, intravenous drug users, dialysis patients, and other high-risk groups.
Screening of blood and blood products before transfusion is another critical preventive strategy. Proper screening has greatly reduced the risk of transfusion-associated HBV infection in many countries. Safe injection practices, avoidance of needle sharing, and proper sterilization of medical and surgical equipment are equally important in controlling disease transmission. Disposable needles and syringes should never be reused, and all reusable instruments must undergo effective sterilization before use.
In healthcare environments, strict adherence to infection-prevention and control measures is essential. Healthcare workers should wear protective equipment such as gloves, masks, laboratory coats, and gowns when handling blood or body fluids. Universal precautions should be applied to all patients and specimens regardless of infection status. Proper disposal of sharps and biomedical waste is necessary to minimize accidental exposure and contamination.
Public health education also plays a major role in disease prevention. Awareness campaigns promoting safe sexual practices, vaccination, and avoidance of contaminated needles can significantly reduce transmission rates. Routine screening of pregnant women allows early detection and prevention of mother-to-child transmission. In addition, antiviral therapy for chronically infected individuals helps suppress viral replication and reduce disease progression and transmission. Effective implementation of these preventive and control strategies remains essential for reducing the global burden of HBV infection.
References
Acheson N.H (2011). Fundamentals of Molecular Virology. Second edition. John Wiley and Sons Limited, West Sussex, United Kingdom.
Alan J. Cann (2005). Principles of Molecular Virology. 4th edition. Elsevier Academic Press, Burlington, MA, USA.
Alberts B, Bray D, Johnson A, Lewis J, Raff M, Roberts K and Walter P (1998). Essential Cell Biology: An Introduction to the Molecular Biology of the Cell. Third edition. Garland Publishing Inc., New York.
Barrett J.T (1998). Microbiology and Immunology Concepts. Philadelphia, PA: Lippincott-Raven Publishers. USA.
Black, J.G. (2008). Microbiology: Principles and Explorations (7th ed.). Hoboken, NJ: J. Wiley & Sons.
Brian W.J Mahy and Mark H.C van Regenmortel (2010). Desk Encyclopedia of Human and Medical Virology. Elsevier Academic Press, San Diego, USA.
Brooks G.F., Butel J.S and Morse S.A (2004). Medical Microbiology, 23rd edition. McGraw Hill Publishers. USA.
Cann A.J (2011). Principles of Molecular Virology. Fifth edition. Academic Press, San Diego, United States.
Carter J and Saunders V (2013). Virology: Principles and Applications. Second edition. Wiley-Blackwell, New Jersey, United States.
Champoux J.J, Neidhardt F.C, Drew W.L and Plorde J.J (2004). Sherris Medical Microbiology: An Introduction to Infectious Diseases. 4th edition. McGraw Hill Companies Inc, USA.
Dimmock N (2015). Introduction to Modern Virology. Seventh edition. Wiley-Blackwell, New Jersey, United States.
Dimmock N.J, Easton A.J and Leppard K.N (2001). Introduction to modern virology. 5th edition. Blackwell Science publishers. Oxford, UK.
Discover more from Microbiology Class
Subscribe to get the latest posts sent to your email.
